Discrepancies in Financial Self-Disclosures and Open Payments Reporting Among Authors of Clinical Oncology Research Studies

2020 ◽  
Vol 38 (5) ◽  
pp. 480-487 ◽  
Author(s):  
Elizabeth Garrett-Mayer ◽  
Melinda W. Kaltenbaugh ◽  
Rebecca Spence ◽  
Suanna S. Bruinooge ◽  
Clifford A. Hudis ◽  
...  
Keyword(s):  
Intellectual Property ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Systematic Comparison ◽  
Consulting Services ◽  
Oncology Research ◽  
Financial Disclosures ◽  
Measures Of Concordance ◽  
Open Payments ◽  
Financial Relationships

PURPOSE Company-reported payments from the Open Payments database (OP) have been compared with self-disclosed financial relationships made by physician authors. Discrepancies have been viewed as under-reporting of financial relationships. Our goal was to perform a systematic comparison to determine sources of discordance between company-reported and self-reported financial relationships. METHODS Financial disclosures reported by 163 authors and presenters who published in Journal of Clinical Oncology or who presented an abstract at the ASCO 2018 Annual Meeting were obtained and matched to payment data in OP. Categories included ownership, research, consulting/services, honoraria, expenses, royalty/patent/intellectual property, and other disclosures. Measures of concordance and discordance were calculated on the basis of matches on both company and category of disclosure and matches on company. Results are reported overall and within certain categories of disclosures. RESULTS Overall concordance between disclosures to ASCO and payments in OP was 16% for company and category matching and 24% for matching on the basis of company only. Authors tended to report more disclosures for research and consulting to ASCO than appear in OP. Expense disclosures were more frequently reported in OP than to ASCO. No payments were categorized as ownership in OP, but 35 authors/presenters disclosed ownership (including stock) to ASCO. CONCLUSION Our results reveal substantial discordance between self-reported and company-reported financial relationships for authors who report clinical oncology research. These findings support the calls for development of standardized disclosure policies across medicine.

Adjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA9084-LBA9084
Author(s):  
M. A. Henderson ◽  
B. Burmeister ◽  
J. F. Thompson ◽  
J. Di Iulio ◽  
R. Fisher ◽  
...  
Keyword(s):  
Lymph Node ◽  
Randomized Trial ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Adjuvant Radiotherapy ◽  
Regional Lymph Node ◽  
Field Control ◽  
Melanoma Patients ◽  
Final Text ◽  
Financial Relationships

LBA9084 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

Carboplatin plus paclitaxel versus carboplatin plus stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Final results of the MITO-2 randomized multicenter trial

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA5508-LBA5508
Author(s):  
S. Pignata ◽  
G. Scambia ◽  
A. Savarese ◽  
R. Sorio ◽  
E. Breda ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Liposomal Doxorubicin ◽  
Advanced Ovarian Cancer ◽  
Multicenter Trial ◽  
Final Text ◽  
Financial Relationships

LBA5508 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

Concomitant CYP2D6 inhibitor use and tamoxifen adherence in early-stage breast cancer: A pharmacoepidemiological study

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. CRA509-CRA509
Author(s):  
V. Dezentje ◽  
N. J. Van Blijderveen ◽  
H. Gelderblom ◽  
H. Putter ◽  
M. P. Van Herk-Sukel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Early Stage ◽  
Early Stage Breast Cancer ◽  
Pharmacoepidemiological Study ◽  
Final Text ◽  
Financial Relationships

CRA509 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. LBA4-LBA4 ◽  
Author(s):  
N. Wolmark ◽  
G. Yothers ◽  
M. J. O'Connell ◽  
S. Sharif ◽  
J. N. Atkins ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Stage Ii ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Carcinoma Of The Colon ◽  
Final Text ◽  
Financial Relationships

LBA4 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

scholarly journals Inconsistencies Between Physician-Reported Disclosures at the AAOS Annual Meeting and Industry-Reported Financial Disclosures in the Open Payments Database

2016 ◽  
Vol 98 (20) ◽  
pp. e90 ◽  
Author(s):  
Charles P. Hannon ◽  
Peter N. Chalmers ◽  
Matthew F. Carpiniello ◽  
Gregory L. Cvetanovich ◽  
Brian J. Cole ◽  
...  
Keyword(s):  
Annual Meeting ◽  
Financial Disclosures ◽  
Open Payments

A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. CRA6509-CRA6509 ◽  
Author(s):  
S. Cheng ◽  
M. Dietrich ◽  
S. Finnigan ◽  
A. Sandler ◽  
J. Crites ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Annual Meeting ◽  
Clinical Oncology ◽  
Development Time ◽  
Final Text ◽  
Financial Relationships ◽  
Sense Of Urgency

CRA6509 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. No significant financial relationships to disclose.

Financial conflicts of interest amongst abstracts, speakers, and planning committee members at the American Society of Clinical Oncology Annual Meeting

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 6635-6635
Author(s):  
K. L. Johnston ◽  
R. S. Go
Keyword(s):  
Annual Meeting ◽  
Clinical Oncology ◽  
Research Funding ◽  
Conflicts Of Interest ◽  
Planning Committee ◽  
Stock Ownership ◽  
Meeting Program ◽  
Financial Conflicts Of Interest ◽  
American Society ◽  
Financial Relationships

6635 Background: Financial conflicts of interest (COI) in medical research are an issue under scrutiny due to a potential risk for biased information. The objective of this study was to survey the extent of self-reported financial relationships with industry amongst abstracts, speakers, and planning committee members at the American Society of Clinical Oncology (ASCO) Annual Meeting. Methods: We used the 2005 and 2006 ASCO meeting program books to tally the total number of abstracts (all types), speakers for education (faculty) and abstract sessions (discussant), as well as planning committee (education and scientific) members (data available only for 2006). The number and nature of financial disclosures were noted. COI categories include: employment, consultant role, stock ownership, honoraria, research funding, expert testimony, or other remuneration. Results are presented as an average over 2 years whenever appropriate. Results: There were approximately 4,396 abstracts presented, 678 speakers, and 301 planners each year. COI were reported in 27%, 46.8%, and 67.4% amongst abstracts presented, speakers, and planners, respectively. Within reported COI, the most common were consultant or advisory role (24.6%), honoraria (21.7%), research funding (21.7%), employment (15.2%), and stock ownership (12.6%). Amongst abstracts with COI, 27.4%, 27.1%, and 45.5% reported 1, 2, or ≥ 3 COI, respectively. Amongst speakers and planners with COI, 35.9%, 38.1%, and 26% reported 1, 2, or ≥ 3 COI, respectively. Notably, COI disclosure was not provided by 14.8% of the speakers on time for the program book publication. Conclusions: Financial COI are prevalent amongst presentations and more so amongst speakers and planners at the ASCO annual meeting. A large proportion of speakers failed to provide disclosure on time. The overwhelming majority of the disclosures were COI other than research funding. While the actual impact of COI on the clinical and research practices of oncologists and researchers cannot be determined from our study, the potential for such influence is significant. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document